Advanced

Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus

Kappelle, Paul J. W. H.; Ahnström, Josefin LU ; Dikkeschei, Bert D.; de Vries, Rindert; Sluiter, Wim J.; Wolffenbuttel, Bruce H. R.; van Tol, Arie; Nielsen, Lars Bo; Dahlbäck, Björn LU and Dullaart, Robin P. F. (2010) In Atherosclerosis 213(1). p.247-250
Abstract
Purpose: Plasma apolipoprotein M (apoM) is potentially anti-atherogenic, and has been found to be associated positively with plasma total, LDL and HDL cholesterol in humans. ApoM may, therefore, be intricately related to cholesterol metabolism. Here, we determined whether plasma apoM is affected by statin or fibrate administration in patients with diabetes mellitus. Methods: Fourteen type 2 diabetic patients participated in a placebo-controlled crossover study which included three 8-week treatment periods with simvastatin (40 mg daily), bezafibrate (400 mg daily), and their combination. Results: ApoM was decreased by 7% in response to simvastatin (P < 0.05 from baseline and placebo), and remained unchanged during bezafibrate and... (More)
Purpose: Plasma apolipoprotein M (apoM) is potentially anti-atherogenic, and has been found to be associated positively with plasma total, LDL and HDL cholesterol in humans. ApoM may, therefore, be intricately related to cholesterol metabolism. Here, we determined whether plasma apoM is affected by statin or fibrate administration in patients with diabetes mellitus. Methods: Fourteen type 2 diabetic patients participated in a placebo-controlled crossover study which included three 8-week treatment periods with simvastatin (40 mg daily), bezafibrate (400 mg daily), and their combination. Results: ApoM was decreased by 7% in response to simvastatin (P < 0.05 from baseline and placebo), and remained unchanged during bezafibrate and combined simvastatin + bezafibrate administration. Plasma apoM concentrations correlated positively with apoB-containing lipoprotein measures at baseline and during placebo (P < 0.02 to P < 0.001), but these relationships were lost during all lipid lowering treatment periods. Conclusions: This study suggests that, even though plasma apoM is lowered by statins, apoM metabolism is to a considerable extent independent of statin-and fibrate-affected pathways involved in cholesterol homeostasis. (C) 2010 Elsevier Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
LDL, HDL cholesterol, Bezafibrate, Apolipoprotein M, Apolipoprotein B, cholesterol, Simvastatin, Type 2 diabetes
in
Atherosclerosis
volume
213
issue
1
pages
247 - 250
publisher
Elsevier
external identifiers
  • wos:000283356400087
  • scopus:77958462840
ISSN
1879-1484
DOI
10.1016/j.atherosclerosis.2010.07.048
language
English
LU publication?
yes
id
db2e2baf-61b7-4a4d-8108-e11b1eebdf17 (old id 1773541)
date added to LUP
2011-02-01 15:43:56
date last changed
2018-07-15 03:02:10
@article{db2e2baf-61b7-4a4d-8108-e11b1eebdf17,
  abstract     = {Purpose: Plasma apolipoprotein M (apoM) is potentially anti-atherogenic, and has been found to be associated positively with plasma total, LDL and HDL cholesterol in humans. ApoM may, therefore, be intricately related to cholesterol metabolism. Here, we determined whether plasma apoM is affected by statin or fibrate administration in patients with diabetes mellitus. Methods: Fourteen type 2 diabetic patients participated in a placebo-controlled crossover study which included three 8-week treatment periods with simvastatin (40 mg daily), bezafibrate (400 mg daily), and their combination. Results: ApoM was decreased by 7% in response to simvastatin (P &lt; 0.05 from baseline and placebo), and remained unchanged during bezafibrate and combined simvastatin + bezafibrate administration. Plasma apoM concentrations correlated positively with apoB-containing lipoprotein measures at baseline and during placebo (P &lt; 0.02 to P &lt; 0.001), but these relationships were lost during all lipid lowering treatment periods. Conclusions: This study suggests that, even though plasma apoM is lowered by statins, apoM metabolism is to a considerable extent independent of statin-and fibrate-affected pathways involved in cholesterol homeostasis. (C) 2010 Elsevier Ireland Ltd. All rights reserved.},
  author       = {Kappelle, Paul J. W. H. and Ahnström, Josefin and Dikkeschei, Bert D. and de Vries, Rindert and Sluiter, Wim J. and Wolffenbuttel, Bruce H. R. and van Tol, Arie and Nielsen, Lars Bo and Dahlbäck, Björn and Dullaart, Robin P. F.},
  issn         = {1879-1484},
  keyword      = {LDL,HDL cholesterol,Bezafibrate,Apolipoprotein M,Apolipoprotein B,cholesterol,Simvastatin,Type 2 diabetes},
  language     = {eng},
  number       = {1},
  pages        = {247--250},
  publisher    = {Elsevier},
  series       = {Atherosclerosis},
  title        = {Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus},
  url          = {http://dx.doi.org/10.1016/j.atherosclerosis.2010.07.048},
  volume       = {213},
  year         = {2010},
}